EGFR and non-small cell lung carcinoma: In several studies, the addition of bevacizumab to first‐generation EGFR‐TKIs (gefitinib or erlotinib) significantly prolonged the PFS in patients with NSCLC with EGFR‐activating mutations compared with gefitinib or erlotinib alone; the OS was not significantly changed.10, 13